Teladoc Health (NYSE:TDOC) 株価情報

Teladoc Health

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

Equities

News

Markets

ETFs

$BTC

ABSI

ARKW

COIN

ROKU

TDOC

VERV

月曜日、Cathie Wood率いるArk Investが一連の大きな取引を行い、その中で最も注目されたのがCoinbase Global Inc.（コインベース）（NASDAQ:COIN）だった。これは、特に暗号通貨市場にとっては不穏な状況の中で行われた取引だ。今回のCOIN売買

アークインベストメント　コインベース株を売却

Teladoc Health Inc

Jefferies analyst Glen Santangelo maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $10 to $8.

Price Target

Analyst Ratings

Jefferies Maintains Hold on Teladoc Health, Lowers Price Target to $8

In the preceding three months, 8 analysts have released ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.25, a high estimate of $16.00, and a low estimate of $8.00. This current average represents a 1.53% decrease from the previous average price target of $12.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372878_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $8.00&#x7C;$9.50 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $16.00&#x7C;$14.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $13.50&#x7C;$11.50 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $11.50&#x7C;$10.50 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $12.00&#x7C;$11.00 &#x7C; 
&#x7C;Michael Wiederhorn &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $12.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teladoc Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately -3.03% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -7.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Teladoc Health

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $9.5 to $8.

B of A Securities Maintains Neutral on Teladoc Health, Lowers Price Target to $8

New features for members and customers include:
<ul>
<li>A premium subscription to <a href="https://www.bettersleep.com">BetterSleep</a>, the award-winning app that promotes sleep quality and well-being.</li>
<li>Access to a registered dietitian for 1:1 support, medical nutrition therapy and personalized nutrition planning.</li>
<li>Proactive outreach from expert health coaches for those at highest risk.</li>
<li>Convenient at-home testing for key cardiometabolic measures, including A1c and blood lipids.</li>
<li>Dynamic health insights that leverage patient-reported data and inputs from Teladoc Health's connected devices— blood glucose meters, blood pressure monitors and connected scales—as well as CGM devices to help empower better outcomes.</li>
<li>Seamless integration with Teladoc Health's 24/7 Care and primary care providers, as well as <a href="https://www.teladochealth.com/organizations/connected-care-partners">connected care partners</a> who can care for related conditions like joint pain and digestive health needs.</li>
</ul>

Health Care

General

Teladoc Health Introduced Its Next Generation Cardiometabolic Health Program To Improve Population Health And Prevent The Progression Of Diabetes, Hypertension And Obesity

Shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) have been under pressure since the fourth-quarter earnings release on Feb. 26.
JPMorgan analysts blamed the persistent underperformance of BetterHelp and "a more challenging operating backdrop complicated by renewed macroeconomic concerns.&#8221;
The Teladoc Health Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beea6/lisa-gill">Analyst Lisa Gill</a> reaffirmed a Neutral rating, while reducing the price target from $13 to $11.
The Teladoc Health Thesis: The company is likely to generate Q1 revenues of $617.5 million, versus consensus of $619 million.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The adjusted EBITDA is likely to be $52.8 million, versus consensus of $53 million, she added.
The analyst projected full-year revenue estimate at $2.52 billion. That&#8217;s slightly higher than the consensus of $2,519 million.
The analyst also has a 2026 estimate of $2.56 billion, versus consensus of $2.558 billion.
Gill lowered the <a>adjusted EBITDA estimates for 2025 and 2026 from $311 million to $294 million and from $333 million to $314 million</a>, respectively.
"Our revenue estimates assume Integrated Care growth of +2% and +3% and we model BetterHelp down -7.7% and flat in FY25 and FY26, respectively," she wrote.
While the scale of Teladoc Health platform and the longer-term strategic direction are good, "there is more work to be done," Gill added.
Price Action: Shares of Teladoc Health had risen by 0.06% to $8.62 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43949618/cisco-and-nvidia-expand-ai-partnership-secure-us-government-authorization-for-cloud-security">Teladoc Health Partners With Eli Liily&#8217;s LillyDirect to Expand Access to Zepbound For Weight Loss</a></li>
</ul>
Photo courtesy of Teladoc
&nbsp;&nbsp;

Analyst Color

Reiteration

Tech

Teladoc Health Q1 Preview: Analyst Says Strategic Direction Is Good, But There's 'More Work To Be Done'

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the <a href="https://www.benzinga.com/general/health-care">healthcare supply chain</a>. 
According to Gill, while Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) direct-to-consumer push is putting pressure on compounding pharmacies, it's not a volume shift that should worry pharmaceutical distributors.
LillyDirect's fulfillment model bypasses traditional distributors by shipping straight from Lilly's warehouses via partners like Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Pharmacy and Truepill.
Read Also: <a href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
That means these sales aren't "lost" volume for distributors—they were never in their lane to begin with. Plus, GLP-1 distribution has never been a major profit driver for pharma distributors, so even if some volume moves from compounding pharmacies to LillyDirect, Gill sees minimal impact on their bottom lines.
<h2 class="wp-block-heading">The Numbers Tell The Story</h2>
LillyDirect's GLP-1 play is still a sliver of the market. Even assuming 5% of 2025's estimated 16.2 million Zepbound prescriptions run through LillyDirect, that's just 800,000 scripts &#8211; a drop in the 4.65 billion-prescription U.S. market bucket. 
Translation? This isn't a disruption; it's a strategic skirmish.
<h2 class="wp-block-heading">A Win For Teladoc?</h2>
One clear winner in this shake-up could be Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>). The company is <a href="https://www.benzinga.com/general/health-care/25/03/44170605/teladoc-health-partners-with-eli-liilys-lillydirect-to-expand-access-to-zepbound-for-weight-loss">integrating LillyDirect into its Chronic Care Weight Management program</a>, potentially boosting enrollments. With GLP-1 costs squeezing insurers, this partnership could make Teladoc's weight management offering more attractive to employers looking for coverage alternatives.
LillyDirect may be making waves, but for pharma distributors, it's business as usual. 
As Gill puts it, the GLP-1 cash-pay trend is more about pressuring compounding pharmacies than upending the broader supply chain. 
Investors eyeing big disruptions might want to look elsewhere.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44182967/weight-loss-drugs-soar-while-global-obesity-rates-climb-to-hit-50-of-adults-by-2050-says-new-report">Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report</a></li>
</ul>
Image: Shutterstock

Biotech

Long Ideas

Trading Ideas

AMZN

Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan

Telemedicine operator Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has entered a pharmacy integration agreement with Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Weight Care Program</a>.
Last year, Eli Lilly&nbsp;announced a&nbsp;new&nbsp;website allowing patients to get a prescription for weight loss through a telehealth provider,&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" rel="noreferrer noopener">marking an industry first</a>.
The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44164208/teladoc-health-adds-glp-1-self-pay-option-to-comprehensive-weight-care" rel="noreferrer noopener">used for obesity treatment</a>.
Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42970274/teladoc-shares-surge-as-amazon-partnership-fuels-push-for-consumer-centric-healthcare" rel="noreferrer noopener">Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare</a>
Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispensing, shipping, delivery, and refills.
Beyond medication access, Teladoc's Comprehensive Weight Care Program offers a multi-disciplinary approach to obesity management. Members receive support from licensed clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;recently introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
In February, Teladoc reported fourth-quarter revenue&nbsp;of $640.5 million, down 3% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43989576/teladoc-health-reports-full-year-and-fourth-quarter-2024-results" rel="noreferrer noopener">consensus estimates</a>.
Price Action: TDOC stock is up 8.02% at $9.75 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44167381/target-hospitality-secures-five-year-lease-with-corecivic-for-dilley-facility-stock-gains" target="_blank" rel="noreferrer noopener">Target Hospitality Secures Five-Year Lease With CoreCivic For Dilley Facility, Stock Gains</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Large Cap

Contracts

Movers

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

WIIM

Teladoc Health shares are trading higher after the company announced a pharmacy integration agreement with Gifthealth for a GLP-1 self-pay option.

Teladoc Announces Pharmacy Integration Agreement With Gifthealth For  GLP-1 Self-Pay Option

In the latest quarter, 8 analysts provided ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $12.88, a high estimate of $16.00, and a low estimate of $11.50. Surpassing the previous average price target of $12.62, the current average has increased by 2.06%.
<img src="https://www.benzinga.com/files/images/story/2025/1741039222_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teladoc Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Teladoc Health's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.03%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -7.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.37%, the company showcases effective utilization of assets.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Teladoc Health Stands With Analysts

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $16 to $13.

Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $13

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Needham Reiterates Hold on Teladoc Healthto Hold

Piper Sandler analyst Jessica Tassan maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and lowers the price target from $13 to $12.

Piper Sandler Maintains Overweight on Teladoc Health, Lowers Price Target to $12

Teladoc shares are trading lower following soft Q1 revenue guidance.

Guidance

Teladoc Sees FY25 Revenue $2.468B-$2.576B vs $2.543B Est., Sees Q1 Revenue $608M-$629M vs $632.911M Est.

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 64.71 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $640.500 million which beat the analyst consensus estimate of $639.552 million by 0.15 percent. This is a 3.03 percent decrease over sales of $660.527 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Teladoc Health Q4 2024 GAAP EPS $(0.28) Misses $(0.23) Estimate, Sales $640.500M Beat $639.552M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

<a href="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/" title="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/">https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/</a>

Short Sellers

Watching Teladoc Health; 'Blue Orca Capital Is Short Teledoc Health' Issues Report On The Company

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and raises the price target from $14 to $16.

Goldman Sachs Maintains Buy on Teladoc Health, Raises Price Target to $16

Press Releases

Teladoc Health Adds GLP-1 Self-Pay Option to Comprehensive Weight Care

Artificial Intelligence Influence on Healthcare Industry Reaching All Time Highs for Diagnostics and Treatments

Teladoc Health Expands Connected Care Partnerships

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

Cylinder joins Teladoc Health's Connected Care Program to expand access to virtual digestive care

Carrum Health Selected by Teladoc Health as Centers of Excellence Partner

AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs

Comments

Teladoc Health

ニュース

パートナーシップ

ベンジンガ・グローバル